This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University

THE WOODLANDS, Texas, April 29, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) announced it is collaborating with Feinberg School of Medicine and the Breast Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in the conduct of a physician sponsored IND investigating the potential for the use of Proellex® in the treatment of breast cancer in a window-of-opportunity design.

The study is being conducted by Seema Khan, MD, Bluhm Family Professor of Cancer Research at Northwestern University Feinberg School of Medicine and co-leader of the Breast Cancer Program.  This will be a randomized, placebo-controlled, pre-surgical trial of oral Proellex at 12 mg daily vs. placebo. The study population will consist of 50 pre-and post-menopausal women with Stage I-III breast cancer found on diagnostic core needle biopsy. The duration of the treatment will be 2-10 weeks depending on the subject's surgical schedule. Assessments of markers of disease will be done both pre-and post-surgically and will include not only markers of hormonal status but markers of proliferation and apoptosis (programmed cell death) in the tumor.

Dr. Seema Kahn noted, "Northwestern is beginning to explore the effects of Proellex (Telapristone, CDB-4124), a new anti-progestin, in women with breast cancer in collaboration with Repros Therapeutics. Progesterone, like estrogen, has been implicated in the causation and progression of breast cancer, based on epidemiological and laboratory data. These data have led to the concept that anti-progesterone therapy could reverse the effects of endogenous female hormones, prompting us to test the potential of novel anti-progestins such as Proellex to treat breast cancer. Furthermore, many primary breast cancers are resistant to anti-estrogenic treatment, and others acquire resistance later in their course, adding to the rationale for the evaluation of this new anti-progesterone in breast cancer. Importantly, Proellex is already in clinical trials in women with benign gynecological conditions that are hormone-dependent, and safety data are reassuring." The trial is funded by the Breast Cancer Research Foundation, with additional support from Repros Therapeutics.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $683.11 -0.15%
TSLA $150.47 4.73%
YHOO $26.76 -1.25%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs